Clinical Trial

Tumor-induced Osteomalacia Disease Monitoring Program

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2021-03-02; most recent amendment 2026-06-02.
Status change: Recruiting → Active, Not Recruiting 2023-02-16
Status change: Not Yet Recruiting → Recruiting 2021-04-26
Trial Details
NCT Number NCT04783428
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Tumor-induced Osteomalacia (TIO)
Enrollment 23 participants
Start Date 2022-01-31
Primary Completion 2032-02-28 (estimated)
Study Completion 2032-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-03